Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Neratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 known ✓ | P04626 | 19/20 | 0.95 |
| ▸ | EGFR known ✓ | P00533 | 19/20 | 0.95 |
| ▸ | ERBB4 known ✓ | Q15303 | 1/20 | 0.95 |
| ▸ | SRC | P12931 | 2/20 | 0.95 |
| ▸ | KDR | P35968 | 2/20 | 0.95 |
| ▸ | STK25 | O00506 | 1/20 | 0.95 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.95 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.95 |
| ▸ | GAK | O14976 | 1/20 | 0.95 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.95 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.95 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.95 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.95 |
| ▸ | STK17B | O94768 | 1/20 | 0.95 |
| ▸ | STK10 | O94804 | 1/20 | 0.95 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.95 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.95 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.95 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.95 |
| ▸ | ABL1 | P00519 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neratinib SCHEMBL29576434 | 1.00 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL29801668 | 1.00 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL30560767 | 1.00 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL29576438 | 1.00 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL28793163 | 1.00 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL2385190 | 1.00 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL19579521 | 1.00 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL30276894 | 1.00 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL2385159 | 1.00 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL29801259 | 1.00 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1777 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4682143-A1 | PHARMACEUTICAL COMPOSITION CONTAINING EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Convalife Pharmaceuticals Co., Ltd. (CN) | 2026-01-21 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| EP-4537108-A1 | ALLELIC IMBALANCE OF CHROMATIN ACCESSIBILITY IN CANCER IDENTIFIES CAUSAL RISK VARIANTS AND THEIR MECHANISMS | Dana-Farber Cancer Institute, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| US-12263226-B1 | Neratinib-cyclodextrin composition and method for preparing same | HANGZHOU JITAI PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-04-01 | — | — | US | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2025029980-A1 | INHIBITION OF HYPOXIA SIGNALING PATHWAY BY PLK1 INHIBITOR | CARDIFF ONCOLOGY, INC. (US) | 2025-02-06 | — | — | WO | claimed |
| EP-2617719-A1 | Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | Wyeth LLC (US) | 2013-07-24 | — | — | EP | claimed |
| US-8394959-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof | WYETH LLC (US) | 2013-03-12 | — | — | US | claimed |
| EP-2537843-A2 | Preparation of maleate salt of neratininb and its use | Wyeth LLC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20120289545-A1 | Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof | LU QINGHONG (US) | 2012-11-15 | — | — | US | claimed |
| US-8173814-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2012-05-08 | — | — | US | claimed |
| US-20110165257-A1 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA | WYETH LLC (US) | 2011-07-07 | — | — | US | claimed |
| EP-2258698-A2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | Wyeth LLC (US) | 2010-12-08 | — | — | EP | claimed |
| EP-2212311-A2 | MALEATE SALTS OF (E)-N-{4-Ý3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO¨-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | Wyeth LLC (US) | 2010-08-04 | — | — | EP | claimed |
| US-20090176827-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2009-07-09 | — | — | US | claimed |
| WO-2009052264-A2 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2009-04-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165257-A1 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA | CHEK1, MAP3K15, KIT | ERBB2 31/4885EGFR 51/4885ERBB4 87/4885 |
| US-20120289545-A1 | Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof | EGFR, ERBB4, ALK | ERBB2 4/4885EGFR 1/4885ERBB4 2/4885 |
| US-20090176827-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | EGFR, ERBB4, ALK | ERBB2 4/4885EGFR 1/4885ERBB4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.